Loading...
Cidara Therapeutics, Inc.
CDTX•NASDAQ
Healthcare
Biotechnology
$61.85
$-0.97(-1.54%)
Cidara Therapeutics, Inc. (CDTX) Financial Performance & Income Statement Overview
Review Cidara Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-98.00%
↓ 98.005%
Operating Income Growth
-619.28%
↓ 619.28%
Net Income Growth
-640.60%
↓ 640.60%
Operating Cash Flow Growth
-686.97%
↓ 686.97%
Operating Margin
-35743.71%
↓ 35743.71%
Gross Margin
81.13%
↑ 81.13%
Net Profit Margin
-59845.03%
↓ 59845.03%
ROE
-131.07%
↓ 131.07%
ROIC
-75.53%
↓ 75.53%
Cidara Therapeutics, Inc. (CDTX) Income Statement & Financial Overview
Review Cidara Therapeutics, Inc.'s (CDTX) income statement with detailed quarterly and annual figures.
| Metric | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $0.00 | $302000.00 | $8.46M | $17.58M |
| Cost of Revenue | $0.00 | $57000.00 | $1.56M | $1.14M |
| Gross Profit | $0.00 | $245000.00 | $6.90M | $16.45M |
| Gross Profit Ratio | $0.00 | $0.81 | $0.82 | $0.94 |
| R&D Expenses | $12.43M | $6.66M | $11.59M | $15.35M |
| SG&A Expenses | $4.96M | $4.69M | $6.00M | $7.17M |
| Operating Expenses | $17.39M | $11.35M | $17.59M | $22.52M |
| Total Costs & Expenses | $17.39M | $11.40M | $19.15M | $23.66M |
| Interest Income | $1.86M | $0.00 | $365000.00 | $527000.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $61000.00 | $57000.00 | $56000.00 | $39000.00 |
| EBITDA | -$17.33M | -$11.06M | -$10.27M | -$6.04M |
| EBITDA Ratio | $0.00 | -$36.57 | -$1.26 | -$0.34 |
| Operating Income | -$17.39M | -$11.10M | -$10.69M | -$6.07M |
| Operating Income Ratio | $0.00 | -$36.76 | -$1.26 | -$0.35 |
| Other Income/Expenses (Net) | $1.86M | $1.77M | $365000.00 | $527000.00 |
| Income Before Tax | -$15.54M | -$94.21M | -$10.33M | -$5.55M |
| Income Before Tax Ratio | $0.00 | -$311.95 | -$1.22 | -$0.32 |
| Income Tax Expense | $0.00 | -$4.80M | -$56000.00 | $64000.00 |
| Net Income | -$15.54M | -$89.41M | -$10.33M | -$5.61M |
| Net Income Ratio | $0.00 | -$296.06 | -$1.22 | -$0.32 |
| EPS | -$2.38 | -$19.59 | -$2.28 | -$1.25 |
| Diluted EPS | -$2.38 | -$19.59 | -$2.28 | -$1.24 |
| Weighted Avg Shares Outstanding | $6.53M | $4.56M | $4.54M | $4.49M |
| Weighted Avg Shares Outstanding (Diluted) | $6.53M | $4.56M | $4.54M | $4.53M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan